Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-α: Histological evaluation by a modified histological activity index scoring system

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 1, 1998, Pages 68-74

  Ninomiya, Toshiaki ^a   Yoon, Seitetsu ^a   Hayashi, Yoshitake ^a   Sugano, Masahiko ^a   Kumon, Yoshiko ^a   Seo, Yasushi ^a   Shimizu, Keiichi ^a   Kasuga, Masato ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Hyaluronic acid; Interferon treatment; Liver fibrosis; Modified histological activity index scoring system

Indexed keywords

ALPHA INTERFERON; COLLAGEN TYPE 4; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; RECURRENT INFECTION; SCORING SYSTEM; VIREMIA;

EID: 0031883758     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.tb00548.x     Document Type: Article

References (26)

1. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
2. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 1995; 22: 696-9.
3. Meyer K, Palmer JW. The polysaccharide of the vitreous humor. J. Biol. Chem. 1934; 107: 629-34.
4. Laurent UBG, Laurent TC. On the origin of hyaluronate in blood. Biochem. Int. 1981; 2: 195-9.
5. Frebourg T, Delpech B, Berciff E et al. Serum hyaluronate in liver diseases: Study by enzymoimmunological assay. Hepatology 1986; 6: 392-5.
6. Engstrom-Laurent A, Loof L, Nyberg A, Schroder T. Increased serum levels of hyaluronate in liver disease. Hepatology 1985; 7: 638-42.
7. Chichibu K, Matumura T, Shichijo S, Yokokawa M. Assay of human hyaluronic acid in clinical application. Clin. Chim. Acta 1989; 181: 317-24.
8. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 1989; 321: 1501-6.
9. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 1989; 321: 1506-10.
10. Camps J, Castilla A, Ruiz J et al. Randomized trial of lymphoblastoid alpha-interferon in chronic hepatitis C. J. Hepatol. 1993; 17: 390-6.
11. Manabe N, Chevallier M, Chossegros P et al. Interferon-alpha (2B) therapy reduces liver fibrosis in chronic non-A hepatitis non-B hepatitis. A quantitative histological evaluation. Hepatology 1993; 18: 1344-9.
12. Guechot J, Loria A, Serfaty L, Giral P, Gibudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: Effect of α-interferon therapy. J. Hepatol. 1995; 22: 22-6.
13. Hiramatu N, Hayashi N, Kasahara A et al. Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha. J. Hepatol. 1995; 22: 135-42.
14. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J. Clin. Invest. 1984; 10: 795-800.
15. Berman B, Duncan MR. Short term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro. J. Am. Acad. Derematol. 1989; 21: 694-702.
16. Tutumi Y, Kakumu S, Yoshioka K, Arao M, Inoue M, Wakita T. Effects of various cytokines on collagen synthesis by normal rat hepatocytes in primary cultures and fibroblasts. Digestion 1989; 44: 191-9.
17. Castillia A, Prieto J, Fausto N. Transforming growth factors β1 and α in chronic liver disease. Effects of interferon alfa therapy. N. Engl. J. Med. 1991; 324: 933-40.
18. Teranaka M, Schenk WG Jr. Hepatic blood flow measurement: A comparison of the indocyanine green and electromagnetic techniques in normal and abnormal flow states in the dog. Ann. Surg. 1977; 185: 58-63.
19. Bachem MG, Riess U, Melchior U, Sell KM, Gressner AM. Transforming growth factors (TGFα and TGE β1) stimulate chondroitin sulfate and hyaluronate synthesis in cultured rat liver fat storing cells. FEBS Lett. 1989; 257: 134-7.
20. Gressner AM, Bachem MG. Cellular sources of noncollagenous matrix proteins: Role of fat-storing cells in fibrogenesis. Semin. Liver Dis. 1990; 11: 30-46.
21. Gibson PR, Fraser JRE, Brown TJ et al. Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology 1992; 15: 1054-9.
22. Ueno T, Inuzuka S, Torimura T et al. Serum hyaluronate reflects hepatic sinusoidal capillarization. Gastroenterology 1993; 105: 475-81.
23. Tamaki S, Ueno T, Torimura T, Sata M, Tanikawa K. Evaluation of hyaluronic acid binding ability of hepatic sinusoidal endothelial cells in rats with liver cirrhosis. Gastroenterology 1996; 111: 1049-57.
24. The French METAVIR Cooperative Study Group. Intra-and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994; 20: 15-20.
25. Ziol M, Tran Van Nhieu J, Roudot-Thoraval F et al. A histological study of the effects of 6-month versus 12-month interferon α-2b therapy in chronic hepatitis C. J. Hepatol. 1996; 25: 833-41.
26. Maharaj B, Maharaj RJ, Leary WP et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; i: 523-5.